Why the study?
Do more potent P2Y12 inhibitors have established efficacy and safety in East Asian populations?
Do more potent P2Y12 inhibitors have established efficacy and safety in East Asian populations?
Answers are grounded in this paper and cite their sources.
There is a debate regarding the efficacy and safety of potent P2Y12 inhibitors in East Asian populations due to a lack of phase III clinical trial data.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Sarma et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: